Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. (Q40468601)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2005

Language	Label	Description	Also known as
English	Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.	scientific article published on February 2005

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. (English)

1 reference

Europe PubMed Central

20 September 2017

Richard T. Wyatt

2

object named as

Richard Wyatt

1 reference

Europe PubMed Central

20 September 2017

author name string

Marie Pancera

1

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

332

1 reference

Europe PubMed Central

20 September 2017

145-156

1 reference

Europe PubMed Central

20 September 2017

1

1 reference

Europe PubMed Central

20 September 2017

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Visualization of fusion activation in the Semliki Forest virus spike.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Structure and function of a paramyxovirus fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

HIV-1 antibody--debris or virion?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.10.042

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2004.10.042

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40468601&oldid=1537864725"